LOS ANGELES, Nov. 5 Response Genetics, Inc.(Nasdaq: RGDX) today announced its President and CEO, Kathleen Danenberg, willprovide a business overview, including an update on its Excision-RepairCross-Complementing 1 (ERCC-1) molecular diagnostic test, at the Rodman &Renshaw 9th Annual Healthcare Conference at the Palace Hotel in New York CityNovember 5-7. Ms. Danenberg will present today at 4:25 p.m. ET.
The presentation will be made available by webcast and can be accessed onthe Media page of Response Genetics' website at www.responsegenetics.com.
Response Genetics, Inc. announced last week that it plans to make its testfor ERCC-1 gene expression for platin-based chemotherapy resistance availableto selected institutions and clinical practice groups in the first quarter of2008. The initial launch will allow gathering of additional data about theutility of ERCC-1 in the treatment of Non-Small Cell Lung Cancer (NSCLC);clinical practice activities such as sample acquisition, logistics, patientand physician communication; and the use of the test in normal clinicalpractice related to NSCLC.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the researchand development of pharmacogenomic cancer diagnostic tests based on itsproprietary and patented technologies. RGI's technologies enable extractionand analysis of genetic information from genes derived from tumor samplesstored as formalin-fixed and paraffin embedded specimens. RGI currentlygenerates revenue primarily from the sales of its proprietary analyticalpharmacogenomic testing services of clinical trial specimens to thepharmaceutical industry. The company was founded in 1999 and its principalheadquarters are located in Los Angeles, California. For more information,please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press releaseand the statements of representatives of Response Genetics, Inc. (the"Company") related thereto contain or may contain, among other things, certainforward-looking statements, within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such forward-looking statements involvesignificant risks and uncertainties. Such statements may include, withoutlimitation, statements with respect to the Company's plans, objectives,projections, expectations and intentions, such as the ability of the Companyto analyze cancer samples, the potential for using the results of thisresearch to develop diagnostic tests for cancer, the usefulness of geneticinformation to tailor treatment to patients, the ability of the Company tomake its ERCC-1 molecular diagnostic test available in the first quarter of2008, or at all, and other statements identified by words such as "projects","may", "could", "would", "should", "believes", "expects", "anticipates","estimates", "intends", "plans" or similar expressions.
These statements are based upon the current beliefs and expectations ofthe Company's management and are subject to significant risks anduncertainties, including those detailed in the Company's filings with theSecurities and Exchange Commission. Actual results, including, withoutlimitation, actual sales results, if any, or the application of funds, maydiffer from those set forth in the forward-looking statements. Theseforward- looking statements involve certain risks and uncertainties that aresubject to change based on various factors (many of which are beyond theCompany's control). The Company undertakes no obligation to publicly updateforward-looking statements, whether because of new information, future eventsor otherwise, except as required by law.
SOURCE Response Genetics, Inc.